DOCSLIB.ORG

Genetic Resistance to Diet-Induced Obesity in Mice

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Genetic Resistance to Diet-Induced Obesity in Mice GENETIC RESISTANCE TO DIET-INDUCED OBESITY IN MICE By LINDSAY CATHERINE BURRAGE Submitted in partial fulfillment of the requirements For the degree of Doctor of Philosophy Thesis Advisors: Dr. Joseph H. Nadeau Dr. Colleen M. Croniger Department of Genetics CASE WESTERN RESERVE UNIVERSITY August, 2006 CASE WESTERN RESERVE UNIVERSITY SCHOOL OF GRADUATE STUDIES We hereby approve the dissertation of ______________________________________________________ candidate for the Ph.D. degree *. (signed)_______________________________________________ (chair of the committee) ________________________________________________ ________________________________________________ ________________________________________________ ________________________________________________ ________________________________________________ (date) _______________________ *We also certify that written approval has been obtained for any proprietary material contained therein. Copyright © 2006 by Lindsay Catherine Burrage All rights reserved 1 TABLE OF CONTENTS 2 LIST OF TABLES. 4 LIST OF FIGURES. 8 ACKNOWLEDGEMENTS . 12 LIST OF ABBREVIATIONS. 14 ABSTRACT. 19 CHAPTER I: INTRODUCTION AND SUMMARY OF RESEARCH AIMS. 21 A. Obesity: An introduction. 22 1. Historical perspective. .22 2. Definition and prevalence of human obesity. 22 3. Causes of human obesity. 26 4. Pathological consequences of obesity. 28 5. Physiologic control of energy balance and body weight. 32 6. Treatment of human obesity. 35 B. Genetics of obesity. 36 1. An introduction to obesity genetics. 36 2. Genetic forms of obesity. 37 C. Methods for investigating the genetics of obesity. 42 1. Genetic studies of obesity in humans. 42 2. Genetic studies of obesity in mouse. 43 D. C57BL/6J and A/J inbred strains: Mouse models for obesity. 52 1. Differential susceptibility to diet-induced obesity in C57BL/6J and A/J male mice. 52 2. Energy metabolism in C57BL/6J and A/J male mice. 54 3. Genetic studies of obesity in C57BL/6J and A/J inbred strains. 55 4. C57BL/6J and A/J: Advantages for complex trait studies. 56 5. B6 –ChrA CSSs accelerate QTL mapping studies in C57BL/6J and A/J strains. 57 E. Summary and research aims. 63 CHAPTER II: GENETIC DISSECTION OF OBESITY IN CHROMOSOME SUBSTITUTION STRAINS. 66 A. Introduction. 67 B. Materials and Methods. 69 C. Results. 78 D. Discussion. 110 CHAPTER III: GENETIC DISSECTION OF OBESITY RESISTANCE ON A/J-DERIVED CHROMOSOME 6. 118 A. Introduction. 119 B. Materials and Methods. 123 C. Results. 129 D. Discussion. 147 3 CHAPTER IV: PHENOTYPIC DISSECTION OF RESISTANCE TO DIET-INDUCED OBESITY IN B6-CHR 6A CHROMOSOME SUBSTITUTION STRAIN MICE. 153 A. Introduction. 154 B. Materials and Methods. 156 C. Results. 160 D. Discussion. 181 CHAPTER V: DISCUSSION AND FUTURE DIRECTIONS. .188 A. Discussion. 189 1. Multiple genes and gene interactions influence obesity resistance. 189 2. CSSs provide models for studying obesity resistance and related traits. 192 3. Evaluation of CSS intercrosses as a method for QTL localization . 193 B. Future Directions. 196 1. How do we identify obesity resistance genes detected in CSSs?. 196 2. How do we identify obesity resistance genes which did not produce peaks in the CSS intercrosses?. 198 3. What mechanism explains the resistance to diet-induced obesity in CSSs and congenic strains?. 202 APPENDICES. 205 A. Appendix I: Genetic markers used in CSS intercross mapping studies. 205 B. Appendix II: Correlations among traits in CSS intercross progeny. 212 B. Appendix III: Multiple QTL analysis in CSS intercross progeny. 233 C. Appendix IV: Genetic and phenotypic analyses of Obrq2. 242 REFERENCES. 264 4 LIST OF TABLES 5 CHAPTER II II-1. Composition of high-fat and low-fat diets. 72 II-2. Three-way ANOVA tables for C57BL/6J and A/J fed diets with varied fat and carbohydrate composition. 81 II-3. Initial HFSC diet CSS survey. 83 II-4. LFCC diet CSS survey. 85 II-5. HFSC vs. LFCC diet CSS survey analysis. 88 II-6. Comparison of replicate HFSC diet CSS surveys. 91 II-7. HFSC diet replicate CSS survey #1. 92 II-8. HFSC diet replicate CSS survey #2. 93 II-9. Trait correlations in B6-ChrA CSS F2 crosses. 96 II-10. LOD scores for B6-ChrA F2 genome scan with p values adjusted for traits analyzed. 97 II-11. LOD scores from B6-ChrA F2 genome scan with p values adjusted for number of crosses and number of traits analyzed. 99 II-12. Support intervals for significant and suggestive QTLs. 100 II-13. QTL inheritance patterns. 103 CHAPTER III III-1. Markers used for congenic panel construction. 126 III-2. FW in the HFSC diet congenic strain survey. 135 III-3. Final BMI for the HFSC diet congenic strain survey. 136 III-4. 62.9-A and 62-BL congenic strain replicate analyses. 137 6 III-5. 62-BL reciprocal cross analysis. 146 CHAPTER IV IV-1. HFSC diet consumption in C57BL/6J, A/J, and B6-Chr 6A males. 167 IV-2. Blood chemistry and liver triglycerides in C57BL/6J (B6), A/J, and B6-Chr 6A at 85 days of age (50 days of high-fat diet consumption). 169 IV-3. Blood chemistry and liver triglycerides in C57BL/6J (B6), A/J, and B6-Chr 6A at 135 days of age (100 days of high-fat diet consumption). 170 IV-4. Metabolic phenotyping in 62-B congenic strain. 175 IV-5. Sterol measurements in C57BL/6J, A/J, B6-Chr 6A (CSS-6), and 62-B congenic strain. 177 IV-6. Amino acid measurements in C57BL/6J, A/J, B6-Chr 6A (CSS-6), and 62-B congenic strain. 179 IV-7. Acylcarnitine profile in C57BL/6J, A/J, B6-Chr 6A (CSS-6), and 62-B congenic strain. 180 APPENDIX III AIII-1. Two dimensional genome scan in B6-ChrA CSS F2 crosses. 236 APPENDIX IV AIV-1. Composition of LabDiet 5010. 246 AIV-2. FW and BMI for 92-A vs. 62-BL after 100 days of 5010 or HFSC diet consumption. 253 7 AIV-3. HFSC diet consumption in 92-A vs. 62-BL males. 256 AIV-4. Blood chemistry in 92-A vs. 62-BL male mice fed the HFSC diet for 28 or 100 days. 257 AIV-5. 62-BL subcongenic HFSC diet survey. 262 8 LIST OF FIGURES 9 CHAPTER I I-1. Energy balance. 24 I-2. Leptin and the melanocortin pathway. 34 I-3. B6-ChrA CSS panel construction. 58 I-4. QTL mapping with CSSs. 60 CHAPTER II II-1. Time course for body weight studies. 73 II-2. C57BL/6J (B6) and A/J weight gain on diets that differ in fat and carbohydrate composition. 79 II-3. C57BL/6J (B6) and A/J body weight (MW, FW, EWG, FWG, and WG) when fed diets that differ in fat and carbohydrate composition. 80 II-4. Correlations between replicate HFSC diet survey traits. 89 II-5. B6-ChrA CSS whole genome scan. 101 II-6. Comparison of CSS surveys and CSS whole genome scan analysis . 104 II-7. FW for B6-ChrA CSS F2 progeny vs. C57BL/6J (B6). 106 II-8. Maternal inheritance was not detected in B6-MitoA . 109 CHAPTER III III-1. Congenic panel derived from B6-Chr 6A. 124 III-2. FW and BMI in the F1 [B6-Chr 6A (CSS-6) x C57BL/6J (B6)] male mice. 131 III-3. FW and BMI in the HFSC diet congenic strain survey. 134 III-4. 62-BL congenic strain HFSC diet replicate analysis. 138 10 III-5. Obrq1 critical interval. 141 III-6. Obrq2 critical interval. 143 III-7. Obrq3 critical interval. 144 III-8. Summary of QTLs discovered on chromosome 6 . 145 CHAPTER IV IV-1. Gonadal fat pad weights and BMI in C57BL/6J (B6) relative to A/J and B6-Chr 6A (CSS-6) fed the HFSC diet for 100 days. 161 IV-2. Pearson’s correlation coefficients for fat pad weight vs. final body weight and fat pad weight vs. BMI in B6-Chr 6A males fed the HFSC diet. 162 IV-3. HFSC diet consumption in C57BL/6J (B6), A/J, and B6-Chr 6A (CSS-6) males. 164 IV-4. B6-Chr 6A (CSS-6) is resistant to the development of fatty liver after 50 days of HFSC diet consumption. 172 IV-5. B6-Chr 6A (CSS-6) is resistant to the development of fatty liver after 100 days of HFSC diet consumption. 173 IV-6. Summary of adiposity, food intake, blood chemistry, and liver triglyceride analyses in C57BL/6J (B6) and B6-Chr 6A male mice fed the HFSC diet for 100 days. 183 IV-7. Summary of adiposity, food intake, blood chemistry, and liver triglyceride analyses in C57BL/6J (B6) and 62-B male mice fed the HFSC diet for 100 days. 185 11 CHAPTER V V-1. Methods for investigating the mechanism of obesity resistance. 204 APPENDIX III AIII-1. Two dimensional genome scan in the B6-ChrA F2 crosses. 240 APPENDIX IV AIV-1. 62-B subcongenic panel. 249 AIV-2. 92-A vs. 62-BL growth curves on 5010 and HFSC diets. .252 AIV-3. HFSC diet consumption in 92-A vs. 62-BL male mice. 255 AIV-4. 62-BL subcongenic HFSC diet survey. ..
Load more

Recommended publications
  • Two Transgenic Mouse Models for Β-Subunit Components of Succinate-Coa Ligase Yielding Pleiotropic Metabolic Alterations
    Two transgenic mouse models for -subunit components of succinate-CoA ligase yielding pleiotropic metabolic alterations Kacso, Gergely; Ravasz, Dora; Doczi, Judit; Németh, Beáta; Madgar, Ory; Saada, Ann; Ilin, Polina; Miller, Chaya; Ostergaard, Elsebet; Iordanov, Iordan; Adams, Daniel; Vargedo, Zsuzsanna; Araki, Masatake; Araki, Kimi; Nakahara, Mai; Ito, Haruka; Gál, Aniko; Molnár, Mária J; Nagy, Zsolt; Patocs, Attila; Adam-Vizi, Vera; Chinopoulos, Christos Published in: Biochemical Journal DOI: 10.1042/BCJ20160594 Publication date: 2016 Document version Publisher's PDF, also known as Version of record Document license: CC BY Citation for published version (APA): Kacso, G., Ravasz, D., Doczi, J., Németh, B., Madgar, O., Saada, A., Ilin, P., Miller, C., Ostergaard, E., Iordanov, I., Adams, D., Vargedo, Z., Araki, M., Araki, K., Nakahara, M., Ito, H., Gál, A., Molnár, M. J., Nagy, Z., ... Chinopoulos, C. (2016). Two transgenic mouse models for -subunit components of succinate-CoA ligase yielding pleiotropic metabolic alterations. Biochemical Journal, 473(20), 3463-3485. https://doi.org/10.1042/BCJ20160594 Download date: 02. okt.. 2021 Biochemical Journal (2016) 473 3463–3485 DOI: 10.1042/BCJ20160594 Research Article Two transgenic mouse models for β-subunit components of succinate-CoA ligase yielding pleiotropic metabolic alterations Gergely Kacso1,2, Dora Ravasz1,2, Judit Doczi1,2, Beáta Németh1,2, Ory Madgar1,2, Ann Saada3, Polina Ilin3, Chaya Miller3, Elsebet Ostergaard4, Iordan Iordanov1,5, Daniel Adams1,2, Zsuzsanna Vargedo1,2, Masatake
    [Show full text]
  • Whole-Genome Microarray Detects Deletions and Loss of Heterozygosity of Chromosome 3 Occurring Exclusively in Metastasizing Uveal Melanoma
    Anatomy and Pathology Whole-Genome Microarray Detects Deletions and Loss of Heterozygosity of Chromosome 3 Occurring Exclusively in Metastasizing Uveal Melanoma Sarah L. Lake,1 Sarah E. Coupland,1 Azzam F. G. Taktak,2 and Bertil E. Damato3 PURPOSE. To detect deletions and loss of heterozygosity of disease is fatal in 92% of patients within 2 years of diagnosis. chromosome 3 in a rare subset of fatal, disomy 3 uveal mela- Clinical and histopathologic risk factors for UM metastasis noma (UM), undetectable by fluorescence in situ hybridization include large basal tumor diameter (LBD), ciliary body involve- (FISH). ment, epithelioid cytomorphology, extracellular matrix peri- ϩ ETHODS odic acid-Schiff-positive (PAS ) loops, and high mitotic M . Multiplex ligation-dependent probe amplification 3,4 5 (MLPA) with the P027 UM assay was performed on formalin- count. Prescher et al. showed that a nonrandom genetic fixed, paraffin-embedded (FFPE) whole tumor sections from 19 change, monosomy 3, correlates strongly with metastatic death, and the correlation has since been confirmed by several disomy 3 metastasizing UMs. Whole-genome microarray analy- 3,6–10 ses using a single-nucleotide polymorphism microarray (aSNP) groups. Consequently, fluorescence in situ hybridization were performed on frozen tissue samples from four fatal dis- (FISH) detection of chromosome 3 using a centromeric probe omy 3 metastasizing UMs and three disomy 3 tumors with Ͼ5 became routine practice for UM prognostication; however, 5% years’ metastasis-free survival. to 20% of disomy 3 UM patients unexpectedly develop metas- tases.11 Attempts have therefore been made to identify the RESULTS. Two metastasizing UMs that had been classified as minimal region(s) of deletion on chromosome 3.12–15 Despite disomy 3 by FISH analysis of a small tumor sample were found these studies, little progress has been made in defining the key on MLPA analysis to show monosomy 3.
    [Show full text]
  • Identification and Characterization of TPRKB Dependency in TP53 Deficient Cancers
    Identification and Characterization of TPRKB Dependency in TP53 Deficient Cancers. by Kelly Kennaley A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Molecular and Cellular Pathology) in the University of Michigan 2019 Doctoral Committee: Associate Professor Zaneta Nikolovska-Coleska, Co-Chair Adjunct Associate Professor Scott A. Tomlins, Co-Chair Associate Professor Eric R. Fearon Associate Professor Alexey I. Nesvizhskii Kelly R. Kennaley [email protected] ORCID iD: 0000-0003-2439-9020 © Kelly R. Kennaley 2019 Acknowledgements I have immeasurable gratitude for the unwavering support and guidance I received throughout my dissertation. First and foremost, I would like to thank my thesis advisor and mentor Dr. Scott Tomlins for entrusting me with a challenging, interesting, and impactful project. He taught me how to drive a project forward through set-backs, ask the important questions, and always consider the impact of my work. I’m truly appreciative for his commitment to ensuring that I would get the most from my graduate education. I am also grateful to the many members of the Tomlins lab that made it the supportive, collaborative, and educational environment that it was. I would like to give special thanks to those I’ve worked closely with on this project, particularly Dr. Moloy Goswami for his mentorship, Lei Lucy Wang, Dr. Sumin Han, and undergraduate students Bhavneet Singh, Travis Weiss, and Myles Barlow. I am also grateful for the support of my thesis committee, Dr. Eric Fearon, Dr. Alexey Nesvizhskii, and my co-mentor Dr. Zaneta Nikolovska-Coleska, who have offered guidance and critical evaluation since project inception.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • An Investigation Into the Genetic Architecture of Multiple System Atrophy and Familial Parkinson's Disease
    An investigation into the genetic architecture of multiple system atrophy and familial Parkinson’s disease By Monica Federoff A thesis submitted to University College London for the degree of Doctor of Philosophy Laboratory of Neurogenetics, Department of Molecular Neuroscience, Institute of Neurology, University College London (UCL) 2 I, Monica Federoff, confirm that the work presented in this thesis is my own. Information derived from other sources and collaborative work have been indicated appropriately. Signature: Date: 09/06/2016 3 Acknowledgements: When I first joined the Laboratory of Neurogenetics (LNG), NIA, NIH as a summer intern in 2008, I had minimal experience working in a laboratory and was both excited and anxious at the prospect of it. From my very first day, Dr. Andrew Singleton was incredibly welcoming and introduced me to my first mentor, Dr. Javier Simon- Sanchez. Within just ten weeks working in the lab, both Dr. Singleton and Dr. Simon- Sanchez taught me the fundamental skills in an encouraging and supportive environment. I quickly got to know others in the lab, some of whom are still here today, and I sincerely appreciate their help with my assimilation into the LNG. After returning for an additional summer and one year as an IRTA postbac, I was honored to pursue a PhD in such an intellectually stimulating and comfortable environment. I am so grateful that Dr. Singleton has been such a wonderful mentor, as he is not only a brilliant scientist, but also extremely personable and approachable. If I inquire about meeting with him, he always manages to make time in his busy schedule and provides excellent guidance and mentorship.
    [Show full text]
  • Mitochondrial Protein Quality Control Mechanisms
    G C A T T A C G G C A T genes Review Mitochondrial Protein Quality Control Mechanisms Pooja Jadiya * and Dhanendra Tomar * Center for Translational Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA * Correspondence: [email protected] (P.J.); [email protected] (D.T.); Tel.: +1-215-707-9144 (D.T.) Received: 29 April 2020; Accepted: 15 May 2020; Published: 18 May 2020 Abstract: Mitochondria serve as a hub for many cellular processes, including bioenergetics, metabolism, cellular signaling, redox balance, calcium homeostasis, and cell death. The mitochondrial proteome includes over a thousand proteins, encoded by both the mitochondrial and nuclear genomes. The majority (~99%) of proteins are nuclear encoded that are synthesized in the cytosol and subsequently imported into the mitochondria. Within the mitochondria, polypeptides fold and assemble into their native functional form. Mitochondria health and integrity depend on correct protein import, folding, and regulated turnover termed as mitochondrial protein quality control (MPQC). Failure to maintain these processes can cause mitochondrial dysfunction that leads to various pathophysiological outcomes and the commencement of diseases. Here, we summarize the current knowledge about the role of different MPQC regulatory systems such as mitochondrial chaperones, proteases, the ubiquitin-proteasome system, mitochondrial unfolded protein response, mitophagy, and mitochondria-derived vesicles in the maintenance of mitochondrial proteome and health. The proper understanding of mitochondrial protein quality control mechanisms will provide relevant insights to treat multiple human diseases. Keywords: mitochondria; proteome; ubiquitin; proteasome; chaperones; protease; mitophagy; mitochondrial protein quality control; mitochondria-associated degradation; mitochondrial unfolded protein response 1. Introduction Mitochondria are double membrane, dynamic, and semiautonomous organelles which have several critical cellular functions.
    [Show full text]
  • REVIEW ARTICLE the Genetics of Autism
    REVIEW ARTICLE The Genetics of Autism Rebecca Muhle, BA*; Stephanie V. Trentacoste, BA*; and Isabelle Rapin, MD‡ ABSTRACT. Autism is a complex, behaviorally de- tribution of a few well characterized X-linked disorders, fined, static disorder of the immature brain that is of male-to-male transmission in a number of families rules great concern to the practicing pediatrician because of an out X-linkage as the prevailing mode of inheritance. The astonishing 556% reported increase in pediatric preva- recurrence rate in siblings of affected children is ϳ2% to lence between 1991 and 1997, to a prevalence higher than 8%, much higher than the prevalence rate in the general that of spina bifida, cancer, or Down syndrome. This population but much lower than in single-gene diseases. jump is probably attributable to heightened awareness Twin studies reported 60% concordance for classic au- and changing diagnostic criteria rather than to new en- tism in monozygotic (MZ) twins versus 0 in dizygotic vironmental influences. Autism is not a disease but a (DZ) twins, the higher MZ concordance attesting to ge- syndrome with multiple nongenetic and genetic causes. netic inheritance as the predominant causative agent. By autism (the autistic spectrum disorders [ASDs]), we Reevaluation for a broader autistic phenotype that in- mean the wide spectrum of developmental disorders cluded communication and social disorders increased characterized by impairments in 3 behavioral domains: 1) concordance remarkably from 60% to 92% in MZ twins social interaction; 2) language, communication, and and from 0% to 10% in DZ pairs. This suggests that imaginative play; and 3) range of interests and activities.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2016/0289762 A1 KOH Et Al
    US 201602897.62A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0289762 A1 KOH et al. (43) Pub. Date: Oct. 6, 2016 (54) METHODS FOR PROFILIING AND Publication Classification QUANTITATING CELL-FREE RNA (51) Int. Cl. (71) Applicant: The Board of Trustees of the Leland CI2O I/68 (2006.01) Stanford Junior University, Palo Alto, (52) U.S. Cl. CA (US) CPC ....... CI2O 1/6883 (2013.01); C12O 2600/112 (2013.01); C12O 2600/118 (2013.01); C12O (72) Inventors: Lian Chye Winston KOH, Stanford, 2600/158 (2013.01) CA (US); Stephen R. QUAKE, Stanford, CA (US); Hei-Mun Christina FAN, Fremont, CA (US); Wenying (57) ABSTRACT PAN, Stanford, CA (US) The invention generally relates to methods for assessing a (21) Appl. No.: 15/034,746 neurological disorder by characterizing circulating nucleic acids in a blood sample. According to certain embodiments, (22) PCT Filed: Nov. 6, 2014 methods for S. a Nial disorder include (86). PCT No.: PCT/US2O14/064355 obtaining RNA present in a blood sample of a patient Suspected of having a neurological disorder, determining a S 371 (c)(1), level of RNA present in the sample that is specific to brain (2) Date: May 5, 2016 tissue, comparing the sample level of RNA to a reference O O level of RNA specific to brain tissue, determining whether a Related U.S. Application Data difference exists between the sample level and the reference (60) Provisional application No. 61/900,927, filed on Nov. level, and indicating a neurological disorder if a difference 6, 2013.
    [Show full text]
  • SUCLG2 Identified As Both a Determinator of CSF Ab1– 42 Levels and an Attenuator of Cognitive Decline in Alzheimer's Disease
    Human Molecular Genetics, 2014, Vol. 23, No. 24 6644–6658 doi:10.1093/hmg/ddu372 Advance Access published on July 15, 2014 SUCLG2 identified as both a determinator of CSF Ab1– 42 levels and an attenuator of cognitive decline in Alzheimer’s disease Alfredo Ramirez1,2,{,∗, Wiesje M. van der Flier6,7,{, Christine Herold8,{, David Ramonet3,{, Stefanie Heilmann2,4, Piotr Lewczuk9, Julius Popp1, Andre´ Lacour8, Dmitriy Drichel8, Eva Louwersheimer6,7, Markus P. Kummer3,8, Carlos Cruchaga10,11, Per Hoffmann2,4,13, Charlotte 6,7 6,7 9 14 15 Teunissen , Henne Holstege , Johannes Kornhuber , Oliver Peters , Adam C. Naj , Vincent Downloaded from Chouraki16,17,Ce´line Bellenguez18,19,20, Amy Gerrish21, International Genomics of Alzheimer’s Project (IGAP){, Alzheimer’s Disease Neuroimaging Initiative (ADNI)}, Reiner Heun1, Lutz Fro¨ lich22, Michael Hu¨ ll23, Lara Buscemi24, Stefan Herms2,4,13, Heike Ko¨ lsch1, Philip Scheltens6,7, Monique M. Breteler8, Eckart Ru¨ ther25, Jens Wiltfang25, Alison Goate10,12, Frank Jessen1,8, http://hmg.oxfordjournals.org/ Wolfgang Maier1,8, Michael T. Heneka3,8,§, Tim Becker5,8,§ and Markus M. No¨ then2,4,§ 1Department of Psychiatry and Psychotherapy, 2Institute of Human Genetics, 3Clinical Neuroscience Unit, Department of Neurology, 4Department of Genomics, Life & Brain Center, 5Institute for Medical Biometry, Informatics, and Epidemiology, University of Bonn, 53127, Bonn, Germany, 6Department of Neurology and Alzheimer Center, Neuroscience Campus Amsterdam, VU University Medical Center, 1081 HZ, Amsterdam, The Netherlands,
    [Show full text]
  • The Protein Arginine Methyltransferase PRMT5 Regulates Proliferation
    The Protein Arginine Methyltransferase PRMT5 Regulates Proliferation and the Expression of MITF and p27Kip1 in Human Melanoma DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University by Courtney Nicholas Graduate Program in Molecular, Cellular, and Developmental Biology The Ohio State University 2012 Dissertation Committee: Gregory B. Lesinski, PhD, Advisor Jiayuh Lin, PhD Amanda E. Toland, PhD Susheela Tridandapani, PhD Copyright by Courtney Nicholas 2012 Abstract The protein arginine methyltransferase-5 (PRMT5) enzyme is a Type II arginine methyltransferase that can regulate a variety of cellular functions. We hypothesized that PRMT5 plays a unique role in regulating the growth of human melanoma cells. Immunohistochemical analysis indicated significant upregulation of PRMT5 in human melanocytic nevi (88% of specimens positive for PRMT5), malignant melanomas (90% positive) and metastatic melanomas (88% positive) as compared to normal epidermis (5% of specimens positive for PRMT5; p<0.001, Fisher’s exact test). Furthermore, nuclear PRMT5 was significantly decreased in metastatic melanomas as compared to primary cutaneous melanomas (p<0.001, Wilcoxon rank sum test). Human metastatic melanoma cell lines in culture expressed PRMT5 predominantly in the cytoplasm. PRMT5 was found to be associated with its enzymatic cofactor Mep50, but not associated with STAT3 or cyclin D1. However, histologic examination of tumor xenografts from athymic mice revealed a heterogeneous pattern of nuclear and cytoplasmic PRMT5 expression. siRNA-mediated depletion of PRMT5 inhibited proliferation in a subset of melanoma cell lines, while it accelerated the growth of others. Loss of PRMT5 also led to reduced expression of MITF (microphthalmia-associated transcription factor), a melanocyte-lineage specific oncogene, and increased expression of the cell cycle regulator p27Kip1.
    [Show full text]
  • Mitochondrial Genetics
    Mitochondrial genetics Patrick Francis Chinnery and Gavin Hudson* Institute of Genetic Medicine, International Centre for Life, Newcastle University, Central Parkway, Newcastle upon Tyne NE1 3BZ, UK Introduction: In the last 10 years the field of mitochondrial genetics has widened, shifting the focus from rare sporadic, metabolic disease to the effects of mitochondrial DNA (mtDNA) variation in a growing spectrum of human disease. The aim of this review is to guide the reader through some key concepts regarding mitochondria before introducing both classic and emerging mitochondrial disorders. Sources of data: In this article, a review of the current mitochondrial genetics literature was conducted using PubMed (http://www.ncbi.nlm.nih.gov/pubmed/). In addition, this review makes use of a growing number of publically available databases including MITOMAP, a human mitochondrial genome database (www.mitomap.org), the Human DNA polymerase Gamma Mutation Database (http://tools.niehs.nih.gov/polg/) and PhyloTree.org (www.phylotree.org), a repository of global mtDNA variation. Areas of agreement: The disruption in cellular energy, resulting from defects in mtDNA or defects in the nuclear-encoded genes responsible for mitochondrial maintenance, manifests in a growing number of human diseases. Areas of controversy: The exact mechanisms which govern the inheritance of mtDNA are hotly debated. Growing points: Although still in the early stages, the development of in vitro genetic manipulation could see an end to the inheritance of the most severe mtDNA disease. Keywords: mitochondria/genetics/mitochondrial DNA/mitochondrial disease/ mtDNA Accepted: April 16, 2013 Mitochondria *Correspondence address. The mitochondrion is a highly specialized organelle, present in almost all Institute of Genetic Medicine, International eukaryotic cells and principally charged with the production of cellular Centre for Life, Newcastle energy through oxidative phosphorylation (OXPHOS).
    [Show full text]
  • THE FUNCTIONAL SIGNIFICANCE of MITOCHONDRIAL SUPERCOMPLEXES in C. ELEGANS by WICHIT SUTHAMMARAK Submitted in Partial Fulfillment
    THE FUNCTIONAL SIGNIFICANCE OF MITOCHONDRIAL SUPERCOMPLEXES in C. ELEGANS by WICHIT SUTHAMMARAK Submitted in partial fulfillment of the requirements For the degree of Doctor of Philosophy Dissertation Advisor: Drs. Margaret M. Sedensky & Philip G. Morgan Department of Genetics CASE WESTERN RESERVE UNIVERSITY January, 2011 CASE WESTERN RESERVE UNIVERSITY SCHOOL OF GRADUATE STUDIES We hereby approve the thesis/dissertation of _____________________________________________________ candidate for the ______________________degree *. (signed)_______________________________________________ (chair of the committee) ________________________________________________ ________________________________________________ ________________________________________________ ________________________________________________ ________________________________________________ (date) _______________________ *We also certify that written approval has been obtained for any proprietary material contained therein. Dedicated to my family, my teachers and all of my beloved ones for their love and support ii ACKNOWLEDGEMENTS My advanced academic journey began 5 years ago on the opposite side of the world. I traveled to the United States from Thailand in search of a better understanding of science so that one day I can return to my homeland and apply the knowledge and experience I have gained to improve the lives of those affected by sickness and disease yet unanswered by science. Ultimately, I hoped to make the academic transition into the scholarly community by proving myself through scientific research and understanding so that I can make a meaningful contribution to both the scientific and medical communities. The following dissertation would not have been possible without the help, support, and guidance of a lot of people both near and far. I wish to thank all who have aided me in one way or another on this long yet rewarding journey. My sincerest thanks and appreciation goes to my advisors Philip Morgan and Margaret Sedensky.
    [Show full text]